Octrin 10 Tablet contains Methoxsalen 10mg, a psoralen derivative used primarily in the treatment of skin disorders such as vitiligo and psoriasis. Methoxsalen acts by intercalating into DNA and, upon activation by ultraviolet A (UVA) light, forms cross-links with pyrimidine bases, leading to inhibition of DNA synthesis and cellular proliferation. This photochemotherapeutic agent enhances the skin’s sensitivity to UVA radiation, facilitating repigmentation in vitiligo and reducing hyperproliferation in psoriasis. Octrin 10 Tablet is indicated for use in conjunction with controlled UVA exposure under medical supervision. The dosage and treatment duration should be individualized based on patient response and tolerance. Patients are advised to avoid excessive sunlight exposure outside of prescribed therapy to minimize the risk of phototoxic reactions. Common adverse effects include nausea, headache, pruritus, and erythema, while long-term use may increase the risk of skin malignancies; therefore, regular monitoring is recommended. Octrin 10 Tablet is contraindicated in patients with hypersensitivity to Methoxsalen, hepatic impairment, or a history of skin cancer. Caution is advised in pregnant or lactating women. Proper adherence to dosing and phototherapy protocols is essential to maximize therapeutic benefits and minimize adverse outcomes.